Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ada C Cleary"'
Autor:
James S. Blachly, Anna Reister Schultz, Maximilian Schmutz, Christopher C. Oakes, Brian J. Druker, Bethany L. Mundy-Bosse, Min Wang, Sebastian Vosberg, Ramiro Garzon, Lars Bullinger, Philipp A. Greif, Ann-Kathrin Eisfeld, Rainer Claus, John C. Byrd, Clara D. Bloomfield, Yue Zhong Wu, Kevin R. Coombes, Brian Giacopelli, Ada C Cleary, Jeffrey W. Tyner
Publikováno v:
Genome Res
Genome Res. 31, 747-761 (2021)
Genome Res. 31, 747-761 (2021)
Acute myeloid leukemia (AML) is a molecularly complex disease characterized by heterogeneous tumor genetic profiles and involving numerous pathogenic mechanisms and pathways. Integration of molecular data types across multiple patient cohorts may adv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::589700731f087a84d637adc67add5af2
https://doi.org/10.1101/gr.269233.120
https://doi.org/10.1101/gr.269233.120
Autor:
Christoph Weigel, Esko Kautto, Elshafa H. Ahmed, Yue-Zhong Wu, Charles T. Gregory, Ada C. Cleary, Sarah Y. Schlotter, Eric Brooks, Mark Lustberg, Robert A. Baiocchi, James S. Blachly, Christopher C. Oakes
Publikováno v:
Blood. 140:8772-8773
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bafc2c62571786ec9f1d4cd3d8770a06
https://doi.org/10.1182/blood-2022-159739
https://doi.org/10.1182/blood-2022-159739
Autor:
Brian Giacopelli, Maria R. Baer, Ann-Kathrin Eisfeld, Kyoko Yamaguchi, Yue-Zhong Wu, James S. Blachly, Salma Abdelbaky, Clara D. Bloomfield, Christopher C. Oakes, Bayard L. Powell, Jessica Kohlschmidt, Kevin R. Coombes, John C. Byrd, Deedra Nicolet, Krzysztof Mrózek, Richard Stone, William Blum, Shelley Orwick, Andrew J. Carroll, Ada C Cleary, Jonathan E. Kolitz
Publikováno v:
Blood. 138:803-803
Genetic profiling of leukemic cells forms the basis for risk stratification in acute myeloid leukemia (AML). Genetic markers in AML are used to make recommendations for distinct treatment approaches, such as remission consolidation with chemotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e98001a5fba51938017c7da4dd3530d
https://doi.org/10.1182/blood-2021-147652
https://doi.org/10.1182/blood-2021-147652
Autor:
Yue-Zhong Wu, Ann-Kathrin Eisfeld, Clara D. Bloomfield, Brian Giacopelli, Min Wang, Kevin R. Coombes, John C. Byrd, Brian J. Druker, Anna Reister Schultz, James S. Blachly, Jeffrey W. Tyner, Ada C Cleary, Christopher C. Oakes
Publikováno v:
Blood. 134:1413-1413
Background Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous disease with poor survival. Recurrent genetic aberrations, such as chromosomal rearrangements and gene mutations, are currently used for patient classification and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7706bc0416cbf5658afd2371352541e9
https://doi.org/10.1182/blood-2019-126212
https://doi.org/10.1182/blood-2019-126212